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Adenovirus is one of the well-studied double-stranded DNA viruses. However, the mechanisms of its DNA packaging and virion
assembly are still not fully understood. One of the unique features of adenovirus is that the unpackaged viral DNA is associated with core
protein pVII. Packaging of viral DNA bound with proteins has not been reported from other viruses. To characterize how viral DNA bound
with protein pVII is packaged, we performed experiments to see if protein pVII interacts with the known DNA packaging proteins or the
packaging sequence. Our results demonstrated that protein pVII interacted with the viral IVa2 and L1 52/55 kDa proteins, which are the
known viral DNA packaging proteins. Furthermore, our protein–DNA binding experiments demonstrated that the IVa2 protein mediates the
specific interaction with the packaging sequence, whereas protein pVII and the L1 52/55 kDa protein bind to DNA non-specifically.
Although the non-specific binding of protein pVII and the L1 52/55 kDa protein do not appear to affect the specific binding of the IVa2
protein to the packaging sequence, and the specific binding of the IVa2 protein does not appear to block the bindings of protein pVII and the
L1 52/55 kDa protein to the packaging sequence, the possibility of a cooperative binding among the IVa2 protein, the L1 52/55 kDa protein
and protein pVII on the packaging sequence needs to be further determined. In summary, the results indicate that the assembly of the DNA
packaging initiation complex may be mediated by the specific interaction of the IVa2 protein with the packaging sequence and other viral
proteins, such as protein pVII and the L1 52/55 kDa protein.
D 2005 Elsevier Inc. All rights reserved.
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Human adenoviruses cause acute respiratory infections in
young children and military recruits (Brandt et al., 1969;
Mallet et al., 1966). They also cause infections in the eye
(Foy et al., 1968), gastrointestinal tract (Wood, 1988), and
urinary bladder (Numazaki et al., 1973). Most of the
adenovirus infections are self-limited in immunocompetent
hosts. However, infections in immunocompromised
patients, such as organ and bone marrow transplant
(BMT) patients and patients with AIDS (Bruno et al.,
2004; Kojaoghlanian et al., 2003), can be disseminated and0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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E-mail address: zhangw2@uthscsa.edu (W. Zhang).lethal. In the past few decades, adenovirus has been used as
a model system to study viral DNA replication, gene
expression, and virus–host interactions and as a potent
vector system for vaccines, for example, potential HIV
vaccines (Shiver and Emini, 2004), and for gene therapy.
Although the biology of adenovirus has been extensively
studied, the mechanisms of viral DNA packaging and virion
assembly are still not fully understood.
The adenovirus virion is an icosahedron which contains a
double-stranded DNA genome of about 36 kbp. The viral
genome is protected by a capsid shell composed of three
major proteins: hexon, penton base, and fiber. It has been
believed that these structure proteins form an empty capsid,
then viral DNA and its associated core proteins are inserted
into the preformed empty capsids. One of the unique
features of adenovirus is that the viral DNA is organized05) 194–202
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virion. The viral core proteins include terminal protein (TP),
proteins VII and V, and peptide mu. The terminal protein is
involved in viral DNA replication and is not required for
viral DNA packaging (Ostapchuk and Hearing, 2003).
Protein VII is the major core protein, and ~1170 to 1350
copies are present in the virion (Prage and Pettersson, 1971).
It has been shown that protein VII has functional features in
common with cellular histones, which condense the viral
DNA (Chatterjee et al., 1986a, 1986b; Fedor and Daniell,
1980; Lischwe and Sung, 1977; Sung et al., 1977; Vayda et
al., 1983). Like protein VII, protein V and peptide mu are
also arginine-rich proteins that are associated with viral
DNA in the core (Anderson et al., 1989; Frearson and
Crawford, 1972; Prage et al., 1968; Russell et al., 1971;
Tagawa et al., 2002; Weber and Anderson, 1988). These
core proteins have been shown to interact with each other
and organize the viral DNA into nucleosome-like structure
in mature virion (Corden et al., 1976; Mirza and Weber,
1982; Vayda et al., 1983). Protein pVII, the precursor of
protein VII, has 23 additional amino acids on the N-terminal
of the protein VII (Lunt et al., 1988). Protein pVII is
packaged into the capsid and cleaved in the virion by a
virus-encoded proteinase into its mature form, VII, to
accomplish the final step of virion maturation. During the
viral infection, the protein VII–DNA complex travels to the
nucleus and may serve as a template for early viral gene
transcription (Haruki et al., 2003; Spector et al., 2003).
Interestingly, protein pVII associates with unpackaged viral
DNA during late phases of viral infection (Brown and
Weber, 1980; Chatterjee et al., 1986a, 1986b; Dery et al.,
1985; Weber and Philipson, 1984). The unpackaged viral
DNA is organized in a manner similar to viral chromatin in
mature virions (Brown and Weber, 1980; Daniell et al.,
1981; Tate and Philipson, 1979; Weber and Philipson,
1984). How such a protein pVII–DNA complex is packaged
into viral capsid is not clear. This situation does not fit the
established models for DNA packaging from other viruses,
such as bacterial phages (Catalano, 2000; Earnshaw and
Casjens, 1980; Fujisawa and Morita, 1997; Guo et al., 1998;
Huang et al., 2004; Serwer, 2003; Smith et al., 2001). Key
questions involve whether protein pVII are packaged
together with DNA or separately. If protein pVII are
packaged with the viral DNA, what roles does protein pVII
play in this process, and how does the viral DNA packaging
motor complex move along DNA bound with protein pVII?
If protein pVII is packaged separately, how does the
packaging motor complex remove protein pVII on the viral
DNA before the viral DNA is packaged? Both possibilities
may require the interaction between protein pVII and the
DNA packaging machinery.
The viral DNA packaging machinery includes the pack-
aging sequence and the proteins that recognize the pack-
aging sequence, which form a DNA packaging initiation
and motor complex. The packaging sequence is located at
the left end of the viral genome (nucleotides 194 to 358 inadenovirus type 5 [Ad5]) (Hammarskjold and Winberg,
1980; Hearing and Shenk, 1983). This region in Ad5
contains several functionally redundant sequence elements
called A repeats. Most of the A repeats have a consensus
motif that is important for DNA packaging (Grable and
Hearing, 1990, 1992; Schmid and Hearing, 1997, 1998). To
package the viral DNA, there should be proteins that
recognize the packaging sequence. Several viral proteins
have been shown to be involved in DNA packaging. One of
these proteins is the L1 52/55 kDa protein. A mutant virus,
which does not express this protein, makes only the empty
capsids containing no viral DNA (Gustin and Imperiale,
1998). Another protein is called IIIa protein. Temperature-
sensitive mutations in this protein cause accumulation of
intermediate particles containing only the left end of the
viral genome at the non-permissive temperature (D’Halluin
et al., 1978; Hasson et al., 1989). A third protein, the IVa2
protein, has been demonstrated to play an important role in
viral DNA packaging. First, the IVa2 protein interacts with
the L1 52/55 kDa protein (Gustin et al., 1996). Second, the
IVa2 protein is the viral protein that is known to bind to the
packaging sequence (Zhang and Imperiale, 2000). A
serotype-specific interaction of the IVa2 protein with the
packaging sequence has been demonstrated to be essential
for viral DNA packaging (Zhang et al., 2001). In addition, a
IVa2-mutant virus does not assemble its capsid properly
(Zhang and Imperiale, 2003). These results indicate that the
IVa2 protein together with other proteins, such as the L1 52/
55 kDa and IIIa proteins may form an initiation and motor
complex around the packaging sequence to mediate viral
DNA packaging. The function of such a motor complex is to
provide energy to packaging viral DNA bound with protein
pVII. This may require a specific interaction of the motor
complex with the protein pVII. It has been suggested that
the IVa2 protein is present in the cores purified from the
disrupted virions (Goding and Russell, 1983; Weber et al.,
1983). The presence of the IVa2 protein in the purified cores
indicates that protein pVII may cooperate with the IVa2
protein and thereby play a role in viral DNA encapsidation.
In this study, we investigated the interaction of the protein
pVII with the viral DNA packaging machinery.Results
Interaction of pVII with the IVa2 protein
Since the viral DNA is associated with protein pVII
before it is packaged, to package such a protein–DNA
complex into viral capsid, it may require a specific
interaction between the viral packaging proteins and protein
pVII. Two of the known proteins, the IVa2 and L1 52/55
kDa proteins, are involved in viral DNA packaging (Gustin
and Imperiale, 1998; Zhang and Imperiale, 2000, 2003;
Zhang et al., 2001). Therefore, we started to investigate
whether protein pVII and its mature form, VII, interact with
Fig. 2. Proteins pVII and VII interact with the IVa2 protein. Immunopre-
cipitation assays were performed using an anti-GFP antibody and different
cell lysates. In panel A, cell lysates were made from 293 cells cotransfected
with pBK-Trip-IVa2 and GFP fusion protein expression vectors (pEGFP-C1
expresses GFP only). In panel B, 293 cells were transfected with different
GFP fusion vectors and then infected with Ad5 at a MOI of 5 pfu/cell. The
precipitated IVa2 protein was detected by immunoblotting using an anti-
IVa2 antibody.
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the proteins VII and pVII with the IVa2 protein, we cloned
the pVII and VII genes into a GFP fusion vector, pEGFP-
C1. The pVII and VII genes were fused to the C terminal of
the GFP. The expression of GFP–pVII and GFP–VII fusion
proteins in transfected 293 cells was demonstrated by
fluorescence microscopy and by immunoblotting with an
anti-GFP antibody (Fig. 1). It has been shown that both pVII
and VII have nucleus and nucleolus colocalization signals
(Lee et al., 2003). In agreement with these previous
findings, we found that both GFP–pVII and GFP–VII
localized to the nucleus (Fig. 1), indicating that proteins
pVII and VII were correctly fused to the GFP. This is
confirmed by the anti-GFP antibody in an immunoblotting
assay (Fig. 1). Although the intensity of the green
fluorescence of both GFP–pVII and GFP–VII fusion
proteins was similar (Fig. 1, the middle two panels);
however, in the whole cell lysate, the amounts of GFP–
pVII were less than that of GFP–VII (Fig. 1, the left penal).
Therefore, we performed experiments to detect GFP–pVII
and GFP–VII in the cell pellet after lysing the cells with our
lysis buffer. We found that the amounts of GFP–pVII in the
cell pellet were more than that of GFP–VII, indicating that
GFP–pVII was associated more with cell pellet, perhaps
cellular DNA, than GFP–VII was.
Then, we cotransfected 293 cells with a IVa2 expression
vector, pBK-Trip-IVa2 (Zhang et al., 2001), and pEGFP–
VII or pEGFP–pVII or pEGFP-C1 (GFP alone). Immuno-
precipitation (IP) assays were performed using the anti-
GFP antibody and lysates from the cotransfected cells. The
precipitated proteins were detected by immunoblotting
with an anti-IVa2 antibody (Zhang and Imperiale, 2003).
Fig. 2A shows that the IVa2 protein was immunoprecipi-
tated in the presence of GFP–VII and GFP–pVII but not in
the presence of GFP alone using anti-GFP antibody. The
results indicated that both protein VII and pVII interact
with the IVa2 protein.
These interactions were further confirmed in virus-
infected cells. We transfected 293 cells with pEGFP–VII
or pEGFP–pVII or pEGFP-C1. Six hours after transfection,
the cells were infected with wild type Ad5 at multiplicity of
infection (MOI) of 5/cell. Twenty four hours after infection,
the cells were harvested to make cell lysates. Immunopre-
cipitation assays were performed using the anti-GFP anti-
body, and the IVa2 protein was detected by immunoblotting.
Similar to the results from the cotransfection assays, theFig. 1. Expression of GFP–pVII and VII fusion proteins. The expression of GFP–
using an anti-GFP antibody (right panel).GFP–VII and GFP–pVII could coprecipitate the IVa2
protein in infected cells whereas GFP alone did not (Fig.
2B). These results indicated that both proteins pVII and VII
interact with the IVa2 protein. Since pVII has 23 additional
amino acids on the N-terminal of the protein (Lunt et al.,
1988) as compared with VII, and both pVII and VII interact
with the IVa2 protein, the first 23 amino acids may not be
part of the IVa2-binding domain, however, it is still possible
that these first 23 amino acids could be involved in
modulate the binding activity.
Interaction of pVII with the L1 52/55 kDa protein
Similar assays were performed to determine whether
protein VII or pVII interacts with the L1 52/55 kDa protein.
In this assay, we used pEGFP–IVa2, a GFP–IVa2 fusion
protein expression vector, as a positive control since the
IVa2 protein interacts with the L1 52/55 kDa protein (Gustin
et al., 1996). The expression of the GFP–IVa2 fusion protein
was confirmed by both anti-GFP and anti-IVa2 antibodies in
immunoblotting assays (data not shown). The L1 52/55 kDa
protein was detected by immunoblotting with an anti-L1
antibody. The results (Fig. 3) indicated that both proteinspVII and VII was detected by fluorescent microscopy and immunoblotting
Fig. 3. Proteins pVII and VII interact with the L1 52/55 kDa protein.
Immunoprecipitation assays were performed using an anti-GFP antibody
and cell lysates from 293 cells transfected with different GFP fusion vectors
and then infected with Ad5 at a MOI of 5 pfu/cell. The precipitated L1 52/
55 kDa protein was detected by immunoblotting using an anti-L1 antibody.
Fig. 4. Specific binding of the IVa2 protein to the packaging sequence.
DNA binding assays were performed using packaging sequence AI–II
repeat (wt) or its mutant form, AI–II-mu (mu), conjugated to magnetic
beads and nuclear extract (NE) from differently treated 293 cells. The IVa2
protein was detected by immunoblotting using an anti-IVa2 antibody.
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infected cells. Since both pVII or VII and the L1 52/55 kDa
protein interact with the IVa2 protein, it is possible that the
interaction detected between pVII or VII with the L1 52/55
kDa protein in infected cells is through the IVa2 protein.
Specific interaction of the IVa2 protein with the packaging
sequence
Since both the IVa2 and L1 proteins are involved in viral
DNA packaging (Gustin and Imperiale, 1998; Zhang and
Imperiale, 2000, 2003; Zhang et al., 2001), the interaction of
protein pVII with the IVa2 and L1 52/55 kDa proteins
suggest that protein pVII may play a role in viral DNA
packaging. Since the IVa2 protein binds to the packaging
sequence, and protein pVII binds to DNA nonspecifically
(Russell and Precious, 1982), we investigated whether the
nonspecific binding of protein pVII interfere with the
formation of the IVa2-complex on the packaging sequence.
To test these, we performed DNA binding protein pull-down
assays using AI–II repeat of the packaging sequence as a
bait. The biotin-labeled AI–II repeats of the packaging
sequence, a mutant AI–II repeats that blocked the IVa2-
specific binding (Zhang and Imperiale, 2000) and a
nonspecific DNA sequence (Table 1) were immobilized on
Streptavidin Magnetic Beads. DNA binding proteins in cell
nuclear extract (NE) were pull-down and detected by
immunoblotting. First, we determined the specificity of
the IVa2 protein on the packaging sequence using this
binding system. As shown in Fig. 4, significant more IVa2
protein was detected to bind to the wild type AI–II
packaging sequence than to the mutant packaging sequence.
This was true when using the NE from both infected cells
and pBK-trip-IVa2 + pEGFP–pVII cotransfected cells.
Furthermore, we observed low levels of nonspecific bindingTable 1




The IVa2 binding motifs and their mutations are underlined.of the IVa2 protein to the mutant AI–II sequence. To
determine whether the mutations in AI–II sequence totally
block the specific binding of the IVa2 protein, we did
experiments using a nonspecific sequence (Table 1) as a
negative control. Similar low levels of nonspecific binding
of the IVa2 protein still existed (data not shown). These
results indicated that the IVa2 protein interact with the
packaging sequence specifically in the binding system,
which is inconsistent with our previous finding (Zhang and
Imperiale, 2000). Furthermore, the presence of GFP–pVII
did not appear to affect the specific binding of the IVa2
protein to the packaging sequence.
Interaction of the protein pVII with the packaging sequence
As demonstrated above, the presence of GFP–pVII did
not affect the specific binding of the IVa2 protein to the
packaging sequence. Next, we determined whether protein
pVII bound to the packaging sequence with or without the
expression of the IVa2 protein. The same reactions used
above (Fig. 4) were immunoblotted to detect GFP–pVII
after the pull-down assay using an anti-GFP antibody. Fig.
5 shows the binding of GFP–pVII to the packaging
sequence. We observed nonspecific binding of GFP–pVII
to DNA with and without the presence of the IVa2 protein.
Similar results were obtained when we used the non-
specific sequence as a control (data not shown). In the
reactions when both protein GFP–pVII and the IVa2
protein were present (Fig. 5, Lane 5), we expected that
the specific binding of the IVa2 protein to the wild type
AI–II sequence would block the nonspecific binding of
GFP–pVII. Interestingly, the specific binding of the IVa2
protein did not block the binding of GFP–pVII to the
packaging sequence. The interaction between the IVa2
protein and protein pVII provided an explanation for this
observation. Protein pVII might remain in the IVa2-TAGTAAATTTGGGCGTAACCGAGTAAGATTTGGCCATTTTCG
TAGTAAATT a cGGCGTAAC t aA t TAAGATTa cGCCATTTTCG
GGGAATTGTAGTATTCTTAAGATGGGAAGTGACGTAATGTGG
Fig. 5. Interaction of protein pVII with the packaging sequence. DNA
binding assays were performed as described in Fig. 4. GFP–pVII fusion
protein was detected by immunoblotting using an anti-GFP antibody.
Fig. 7. Specificity of the DNA binding assays. DNA binding assays were
performed as described in Fig. 4. After binding, E1A proteins and h-actin
were detected by immunoblotting using anti-E1A and anti-h-actin anti-
bodies (Lanes 1 and 2). Lanes 3 and 4 detected the E1A protein and h-actin
in the NE of 293 cells or Ad5-infected 293 cells.
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the IVa2 protein. However, it is still possible that protein
pVII and the IVa2 protein bind to the packaging sequence
on separate probes or different binding sites.
Interaction of the L1 52/55 kDa protein with the packaging
sequence
Since the L1 52/55 kDa protein is required for viral DNA
encapsidation (Gustin and Imperiale, 1998), and it interacts
with the IVa2 protein and protein pVII, we investigated
whether the L1 52/55 kDa protein is a component of the
protein complex formed with the packaging sequence.
Similar binding assays as above were performed using
nuclear extracts from viral infected cells. The L1 protein
was detected with an anti-L1 antibody. We found that the L1
52/55 kDa protein bound to DNA nonspecifically. Equal
amount of L1 52/55 kDa protein was pulled down by both
wild type AI–II repeat and the mutant AI–II (Fig. 6). In a
separate experiment, we tested whether the L1 52/55 kDa
protein bound to a nonspecific DNA sequence (Table 1). We
found that the L1 52/55 kDa protein could bind to the
nonspecific DNA as well (data not shown). These results
indicated that the L1 protein could interact with DNA
nonspecifically. Since the IVa2 protein bound to wild type
AI–II specifically, similar to the binding property of protein
pVII, the specific binding of the IVa2 protein did not appear
to block the binding of the L1 52/55 kDa protein to the wild
type AI–II. Furthermore, the binding of L1 52/55 kDa
protein to wild type AI–II did not appear to affect the
specific binding of the IVa2 protein detected in the assay
above (Fig. 4). In the presence of the IVa2 protein, it isFig. 6. Interaction of the L1 52/55 kDa protein with the packaging
sequence. DNA binding assays were performed as described in Fig. 4.
GFP–pVII fusion protein was detected by immunoblotting using an anti-L1
antibody.possible that the binding of the 52/55 kDa protein to the
packaging sequence is mediated by the interaction with the
IVa2 protein. However, another possibility is that these two
proteins may bind to the packaging sequence on separate
probes or different binding sites.
Since we found that the L1 52/55 kDa protein and
protein pVII interacted with DNA nonspecifically, we next
determined whether other viral or cellular proteins bound to
DNA nonspecifically in our binding assay conditions. We
examined the viral E1A protein and the h-actin cellular
protein. Fig. 7 showed that both E1A protein and h-actin
were detected in Ad5-infected and uninfected 293 cells,
however, they were not detected in the DNA binding pull-
down products. These result indicated that our in vitro
binding conditions did not favor binding of all the proteins
to DNA, and that the interaction of the L1 52/55 kDa protein
with DNA might not be an artifact of the assay.Discussion
An established model for viral DNA packaging comes
from studies of many bacteriophages, in which viral DNA is
packaged into preformed capsid shells (Catalano, 2000;
Earnshaw and Casjens, 1980; Fujisawa and Morita, 1997;
Guo et al., 1998; Huang et al., 2004; Serwer, 2003; Smith et
al., 2001)). Among mammalian viruses, herpesviruses,
including herpes simplex virus (HSV) and cytomegalovirus
(CMV) have been described to use a similar pathway as
phage E to package its DNA (Newcomb et al., 1994, 1996;
Newcomb et al., 2001; Savva et al., 2004; Stow, 2001;
White et al., 2003). Several lines of evidence suggest that
adenovirus may use a similar pathway to package its DNA.
Empty capsids are produced in parallel to mature virions in
infected cells (Sundquist et al., 1973). Intermediate particles
with buoyant densities between empty capsids and mature
virions have been isolated from infected cells. These
intermediates contain small DNA fragments that are mainly
Fig. 8. Packaging of DNA–pVII complex.
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Kinetic radiolabeling and pulse-chase studies suggest that
empty capsids and intermediate particles are precursors of
mature virions (Horwitz et al., 1969; Ishibashi and Maizel,
1974; Sundquist et al., 1973). A unique feature of
adenoviruses is that there are histone-like protein pVII
bound to viral DNA before the viral DNA is packaged
(Brown and Weber, 1980; Chatterjee et al., 1986a, 1986b;
Dery et al., 1985; Weber and Philipson, 1984). Packaging of
virus DNA bound with proteins has not been reported from
studies of other viruses. We proposed that to package such a
protein–DNA complex, interactions between protein pVII
and DNA packaging proteins should occur. Our results that
protein pVII interacts with the IVa2 and L1 proteins
supports this assumption.
Previously, we have shown that the IVa2 protein interacts
with the packaging sequence and is involved in viral DNA
packaging and virion assembly (Zhang and Imperiale, 2000,
2003; Zhang et al., 2001). The IVa2 protein is a component
of two DNA–protein complexes formed with the packaging
sequence. These experiments were performed using electro-
phoresis mobility shift assays. In this study, we confirmed
these previous studies with a different in vitro binding
system. We have found that the IVa2 protein is a component
that determines the specificity of the interaction of the
packaging sequence-protein complex. Consistent with the
previous finding (Russell and Precious, 1982), protein pVII
binds to DNA nonspecifically. However, the nonspecific
binding of protein pVII does not interrupt with the specific
binding of the IVa2 protein with the packaging sequence.
Furthermore, with the specific binding of the IVa2 protein,
protein pVII is still present in the complex with the
packaging sequence. Similar situation may be true for the
L1 52/55 kDa protein. These results indicate that the
assembly of the DNA packaging initiation complex may
be mediated by the specific interaction of the IVa2 protein
with the packaging sequence and other viral proteins, such
as protein pVII and the L1 52/55 kDa protein. The results of
this study provided the molecular bases to understand how
DNA–pVII complex is packaged into capsid.
Based on our results, there may be three possible ways
for a DNA–protein complex to be packaged into capsid. The
first possibility is that viral DNA is transferred into the
capsid with the bound protein pVII (Fig. 8A). Therefore, the
DNA packaging initiation and motor complex will have to
transfer viral DNA covered with protein pVII. This would
be a novel mechanism of DNA packaging, which has not
been previously described. If this is the case, then
interaction of protein pVII with the DNA packaging protein
is likely involved, which is supported by our data that
protein pVII interacts with the IVa2 protein. The second
possibility is that the DNA packaging machinery only
transfers naked DNAwithout protein pVII (Fig. 8B). Protein
pVII may penetrate the capsid freely so that it can be
associated with the packaged DNA again to form the
chromatin-like structure in the capsid. If this is true, then aninteresting question is how the DNA packaging motor strips
protein pVII off to make the DNA ready for packaging.
Very recently, it has been shown that a protein in yeast,
called Rad54, can mediate chromatin remodeling and
remove the nucleosome proteins off the cellular DNA
(Alexeev et al., 2003). It is possible that a similar
mechanism is used by the viral DNA packaging machinery
to remove protein pVII from the viral DNA in this case. The
third possibility is that protein pVII and DNA form a
chromatin-like structure first, and then the viral capsid
proteins assemble around it (Fig. 8C). There is no direct
evidence to support this possibility; however, there are other
viruses may use this model to package their viral genome.
Poliovirus is one of the viruses that may assemble its
structural proteins around the genome, which is RNA in this
case (Putnak and Phillips, 1981; Rombaut et al., 1990;
Verlinden et al., 2000). Among the DNA viruses, simian
virus 40 is thought to assemble its capsid around its circular
DNA genome. Recently, it has been shown that a cellular
factor, Sp1, recruits two of the capsid proteins, VP2 and
VP3, to the viral packaging signal to form a packaging
center around which VP1, the major capsid protein,
assembles (Gordon-Shaag et al., 2002). Whether this is true
for adenovirus DNA packaging requires more direct
evidence.
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Cell culture
All cell lines were maintained in Dulbecco’s modified
Eagle medium (DMEM) with 10% fetal bovine serum
(FBS), at 37 8C in a 5% CO2 incubator. Infection of 293
cells, a human embryonic kidney cell line that express
adenovirus type 5 (Ad5) E1A and E1B proteins, was carried
out as described previously (Zhang and Imperiale, 2003).
Plasmids
The pVII and VII genes were amplified by PCR using
the following two different forward primers, GCGCGG-
ATCCGCAAGCATGTCCATCCTTATA and GCGCGGA-
TCCGCC ACCATGGGCGGGGCCAAGAAGCGCT, and
a shared reverse primer, GCGCCTCGAGAA CAGTACG-
AGTCTAAGTAGT. First, pVII and VII genes were cloned
into the pBK-CMV vector at the BamHI and XhoI sites to
generate pBK-pVII and pBK-VII. Then, pBK-pVII and
pBK-VII were digested with BamHI and KpnI to release the
pVII and VII fragments. pEGFP–pVII and pEGFP–VII
were generated by cloning the BamHI-plus-KpnI digested
pVII and VII fragments from pBK-pVII and pBK-VII into
the BglII and KpnI sites of pEGFP-C1. Similarly, to
generate pEGFP–IVa2, the IVa2 DNA fragment was
released from pBK-Trip-IVa2 (Zhang and Imperiale, 2003)
with BamHI and KpnI and cloned into the BglII and KpnI
sites of pEGFP-C1.
Transfections
293 cells were transfected with pEGFP-(C1, pVII, VII,
IVa2) either alone, or cotransfected with pBK-trip-IVa2.
Transfections were performed by the calcium phosphate
method. 293 cells were plated 1 day prior to transfection and
the medium from the cells was changed 3 h before
transfection. Sterile, deionized water and the DNA (10 Ag)
were prepared in a sterile conical to a total volume of 250 Al
together. Then, 300 Al of 2 HBS (50 mM HEPES, 280
mM NaCl, 1.5 mM Na2HPO4, pH: 7.05), and 50 Al of 2 M
CaCl2 were added to the solution. After the addition of the
CaCl2, the solution was mixed slowly with a sterile pipette.
Then, the solution was incubated for 30 min at room
temperature. The total solution was added to subconfluent
cells in 60-mm-diameter dishes drop by drop while slowly
rocking. The cells were incubated for 16 h at 37 8C in a CO2
incubator.
Immunoprecipitation
Cell lysates were made from the cotransfected or
transfected + infected cells as described (Harris et al.,
1996). Cell lysates were incubated with 5 Al of anti-GFP
antibody (Roche Diagnostic Corporation) for 1 h on ice.Then, the samples were incubated with 25 Al of protein-G-
Agarose beads for 3–12 h at 4 8C with rocking. Immunol-
complexes bound to the beads were washed three times with
lysis buffer for 10 min while rotating at 4 8C. All traces of
lysis buffer were removed by a quick centrifugation and
removal of the supernatants. Immunol-complexes bound to
beads were released into gel-loading buffer (2% sodium
dodecyl sulfate [SDS], 60 mM Tris [pH 6.8], 10% glycerol,
0.1% bromophenol blue, 292 mM h-mercaptoethanol) by
boiling for 3–5 min at 95 8C. Samples were resolved by
SDS-PAGE with 10% polyacrylamide and the gels were
subjected to immunoblotting.
Immunoblotting
Following SDS-PAGE, proteins were transferred to
nitrocellulose membrane in 25 mM Tris-200 mM
glycine–20% methanol for 90 min at 65 V and 4 8C.
After transfer, the membrane was placed in blocking
solution of 5% nonfat dried milk in PBS-T (PBS plus
0.1% Tween 20) for 1 h at room temperature with
rocking. Then, the membrane was incubated in blocking
solution containing the primary antibody for 90 min at
room temperature with rocking. Afterwards, the mem-
brane was washed three times in PBS-T for 10 min each
with rocking, and incubated in blocking solution with the
secondary antibody (horseradish peroxidase linked) for
1 h at room temperature with rocking. The membrane
was then washed three times in PBS-T as stated above,
and then developed with enhanced chemiluminescence
reagents (Amersham). For reprobing, the membranes
were stripped in stripping buffer (100 mM 2-mercaptoe-
thanol, 2% SDS, 62.5 mM Tris–HCl [pH 6.7]) at 50 8C
for 30 min while rotating and then reprobed as described
above.
DNA-binding protein pull-down assay
Packaging sequence-binding proteins were detected
using AI–II repeat as a bait immobilized on magnetic
streptavidin beads (Roche Diagnostic Corporation). First,
the 25 Al of the magnetic streptavidin beads were washed
three times with 50 Al TEN100 Binding Buffer (10 mM
Tris–HCl, 1 mM EDTA, 100 mM NaCl, pH 7.5). Then,
0.5 Ag of biotin-labeled AI–II, mutant AI–II or a non-
specific double-stranded DNA sequence (Table 1) was
added to the beads in 50 Al TEN100 Binding Buffer and
incubated for 15 min at room temperature to conjugate the
biotinylated DNA to the magnetic streptavidin beads. The
mixture was then washed two times with 200 Al TEN1000
Binding Buffer (10 mM Tris–HCl, 1 mM EDTA, 1 M
NaCl, pH 7.5), and washed two times with 200 Al
Reaction Buffer (10 mM HEPES [pH 7.9], 20 mM KCl,
3 mM MgCl2, 100 mM EDTA, 12% Glycerol, 1 mM
DTT). Next, the protein binding reaction was prepared by
mixing 65 Al Reaction Buffer, 6.25 Al polyD (IC) [0.5 Ag/
W. Zhang, R. Arcos / Virology 334 (2005) 194–202 201Al], 3.13 Al poly-l-lysine [0.1%], 10 Al nuclear extract;
and the reaction was incubated for 30 min at room
temperature with 50 Al of the washed beads. Cell nuclear
extracts were prepared as described previously (Zhang and
Imperiale, 2000). After incubation, the reaction was
washed with 200 Al Reaction Buffer three times. The
proteins were resolved by SDS-PAGE and analyzed by
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